Itolizumab

DRUG8 trials

Conditions

Acute GVHDAcute Graft Versus Host DiseaseAcute Respiratory Distress SyndromeAcute-graft-versus-host DiseaseCOVID-19 COVID-19 SARS-CoV-2COVID-19 COVID-19 SARS-CoV2Dermatomyositis, Adult TypeGVHD

Phase 1

Safety and Clinical Activity of Itolizumab in aGVHD

NCT05823675

Biotech Pharmaceutical Co., Ltd.Acute Graft Versus Host Disease

Start: 2023-05-19End: 2025-02-28Target: 44Updated: 2023-05-25

Safety and Preliminary Clinical Activity of Itolizumab in ARDS

NCT05978544

Biotech Pharmaceutical Co., Ltd.Acute Respiratory Distress Syndrome

Start: 2023-12-31End: 2025-12-31Target: 38Updated: 2023-08-07

Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis

NCT05986162

Biotech Pharmaceutical Co., Ltd.Dermatomyositis, Adult Type

Start: 2023-12-30End: 2025-06-25Target: 44Updated: 2023-08-14

Phase 3

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

TerminatedNCT05263999

EquilliumAcute-graft-versus-host Disease, Acute GVHD, aGVHD +2

Start: 2022-04-29End: 2025-05-12Updated: 2025-06-17

Unknown Phase

Treatment of SARS CoV-2 pneumonia with the anti-CD6 monoclonal antibody itolizumab

RecruitingRPCEC00000311

Center of Molecular Immunology (CIM)severe SARS-CoV-2 pneumonia COVID-19 SARS-CoV-2

Start: 2020-03-28Target: 80Updated: 2026-03-30

Itolizumab Safety and Efficacy Study in Covid 19

Active, not recruitingRPCEC00000361

Center of Molecular Immunology(CIM)COVID-19 COVID-19 SARS-CoV-2

Start: 2021-04-01Target: 20Updated: 2026-03-30

Itolizumab-Plasmapheresis in patients with COVID-19

Active, not recruitingRPCEC00000380

Center of Molecular ImmunologyCOVID-19 COVID-19 SARS-CoV2

Start: 2021-09-27Target: 50Updated: 2026-03-30

Post EUA study of Itolizumab in COVID-19

Active, not recruitingRPCEC00000402

Center of Molecular Immunology (CIM)Pneumonia by SARS-CoV-2

Start: 2020-09-13Updated: 2026-03-30

Related Papers

Primary results from Equator, a Phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease.

Blood2025-11-031 citations

Treatment of Systemic Inflammation with Itolizumab: A Single Center Experience

Archives of Clinical and Medical Case Reports2022-01-01

An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.

2020-11-1420 citations